Literature DB >> 16161179

Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis.

Bence Sipos1, Motohiro Kojima, Katharina Tiemann, Wolfram Klapper, Marie-Luise Kruse, Holger Kalthoff, Bodo Schniewind, Jürgen Tepel, Herbert Weich, Dontscho Kerjaschki, Günter Klöppel.   

Abstract

Early lymph node metastasis is common in pancreatic ductal adenocarcinoma (PDAC). The present study has examined the relationship of lymphatic spread to lymph vessel development and the expression of lymphangiogenic cytokines in a series of well-characterized PDACs. The hot spot method revealed the intratumoural and peritumoural lymphatic vessel density (LVD) to be slightly higher in PDACs than in the normal pancreas. The average intratumoural LVD, however, was strikingly decreased. There was no overexpression of vascular endothelial growth factor (VEGF)-C and VEGF-D in PDACs compared with the normal pancreas. LVD and expression of lymphangiogenic cytokines were not related to any of the biological tumour features or to patient survival. Three orthotopic nude mouse PDAC models did not reveal any increase in tumour-associated LVD, despite a high rate of lymph node metastasis. Lymph vessel proliferation was comparable in PDAC and chronic pancreatitis, in both humans and mice. In conclusion, increased lymphangiogenic activity is not required for and does not significantly affect the lymphatic spread of PDAC. The reduced number of human and murine intratumoural lymph vessels indicates that lymphatic metastasis takes place predominantly via peritumoural lymphatic vessels. The weak expression of lymphangiogenic cytokines in neoplastic cells and lymphatic vessel proliferation in peritumoural regions and chronic pancreatitis indicate that inflammation may be the reason for the low rate of lymphangiogenesis. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16161179     DOI: 10.1002/path.1840

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  22 in total

1.  In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis.

Authors:  Inés Martínez-Corral; David Olmeda; Rodrigo Diéguez-Hurtado; Tuomas Tammela; Kari Alitalo; Sagrario Ortega
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

Review 2.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 3.  Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?

Authors:  Sunny Y Wong; Richard O Hynes
Journal:  Cell Cycle       Date:  2006-04-17       Impact factor: 4.534

Review 4.  Lymphangiogenesis and lymphatic vessel remodelling in cancer.

Authors:  Steven A Stacker; Steven P Williams; Tara Karnezis; Ramin Shayan; Stephen B Fox; Marc G Achen
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

5.  VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner.

Authors:  Seiji Shigetomi; Yorihisa Imanishi; Katsushi Shibata; Nobuya Sakai; Koji Sakamoto; Ryoichi Fujii; Noboru Habu; Kuninori Otsuka; Yoichiro Sato; Yoshihiro Watanabe; Masayuki Shimoda; Kaori Kameyama; Hiroyuki Ozawa; Toshiki Tomita; Kaoru Ogawa
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

Review 6.  Molecular mechanisms of lymphatic metastasis in solid tumors of the gastrointestinal tract.

Authors:  Melanie C Langheinrich; Vera Schellerer; Aristotelis Perrakis; Clemens Lohmüller; Claus Schildberg; Elisabeth Naschberger; Michael Stürzl; Werner Hohenberger; Roland S Croner
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

Review 7.  Potential therapeutic strategies for lymphatic metastasis.

Authors:  Bernadette M M Zwaans; Diane R Bielenberg
Journal:  Microvasc Res       Date:  2007-09-19       Impact factor: 3.514

8.  Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro.

Authors:  S Madlener; P Saiko; C Vonach; K Viola; N Huttary; N Stark; R Popescu; M Gridling; N T-P Vo; I Herbacek; A Davidovits; B Giessrigl; S Venkateswarlu; S Geleff; W Jäger; M Grusch; D Kerjaschki; W Mikulits; T Golakoti; M Fritzer-Szekeres; T Szekeres; G Krupitza
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

9.  Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis.

Authors:  Lucie Kopfstein; Tanja Veikkola; Valentin G Djonov; Vanessa Baeriswyl; Tibor Schomber; Karin Strittmatter; Steven A Stacker; Marc G Achen; Kari Alitalo; Gerhard Christofori
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

10.  Fluorescent LYVE-1 antibody to image dynamically lymphatic trafficking of cancer cells in vivo.

Authors:  Michele McElroy; Katsuhiro Hayashi; Barbara Garmy-Susini; Sharmeela Kaushal; Judith A Varner; A R Moossa; Robert M Hoffman; Michael Bouvet
Journal:  J Surg Res       Date:  2008-01-18       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.